Drug developer Depomed Inc announced it would recall 52 lots of its type 2 diabetes drug Glumetza due to the presence of traces of a certain chemical in the tablet’s 500 mg bottle, according to a Reuters report.
The recall followed an investigation of a single product complaint of a smell and taste consistent with the chemical, the company said in a regulatory filing.
The recall does not impact the 1,000 mg formulation, which currently constitutes about 40 percent of total Glumetza net product sales, Depomed said.
Glumetza (metformin hydrochloride) extended release tablet is an oral antihyperglycemic drug used in the management of type 2 diabetes.
